E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research

Online Publishing Date:
29 / 12 / 2015

 


Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami.


Abstract
Background: Atherosclerosis is a chronic inflammation disease that is caused by the interaction between monocyte and endothelial injury in tunica intima. One of the major factor of atherosclerosis is dyslipidemia. Chronic dyslipidemia, especially hypercholesterolemia, can directly alter endothelial cell through reactive oxygen species (ROS) production that oxidizes low-density lipoprotein (LDL) to become oxidized LDL (Ox-LDL). Proinflammatory cytokines, the products of perivascular adipocyte tissue (PVAT), may draw macrophage. Macrophage then engulfs Ox-LDL and becomes foam cell within tunica intima. Lipoprotein-associated phospholipase A2 (Lp-pLA2) is an enzyme that cleaves Ox-LDL to become proatherosclerotic products. Darapladib, an Lp-pLA2 inhibitor, is expected to inhibit atherosclerotic lesion progressivity.

Aims and Objective: To know the effects of darapladib on Ox-LDL level, PVAT thickness, and foam cell number.

Materials and Methods: This study used in vivo posttest controlled group design with two time series. Thirty male Sprague–Dawley rats divided into two group based on time series (8 weeks and 16 weeks). Each time serial was divided into three groups which were: standard diet group ;high-fat diet group; and dyslipidemia model with darapladib administration group with dose of 200 mg/200 g body weight (BW). The parameters that was measured in this study were lipid profile [total cholesterol, LDL/very-low-density lipoprotein (VLDL), and high-density lipoprotein (HDL)], Ox-LDL level, number of foam cells, and PVAT thickness.

Result: Ox-LDL level and foam cell number decreased significantly (p = 0.000 and p = 0.005, respectively), while PVAT thickness did not show significant difference (p = 0.912).

Conclusion: In this, study, it has been proven that darapladib decreases Ox-LDL levels and foam cell numbers but not in PVAT thickness, even though a decreasing pattern was observed histologically. Further study needed to know the optimum dosage of darapladib administration.

Key words: Darapladib; Lp-PLA2; Ox-LDL; Foam Cell; PVAT; Dyslipidemia


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Teuku Heriansyah
Articles by Titin Andri Wihastuti
Articles by Kenty Wantri Anita
Articles by Agustin Iskandar
Articles by Riski Bagus Suhendra
Articles by Patan Ahmad Setiabudi
Articles by Lintang Widya Sishartami
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats. Natl J Physiol Pharm Pharmacol. 2016; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580


Web Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats. https://www.njppp.com/?mno=203195 [Access: March 14, 2024]. doi:10.5455/njppp.2015.5.2909201580


AMA (American Medical Association) Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats. Natl J Physiol Pharm Pharmacol. 2016; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580



Vancouver/ICMJE Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats. Natl J Physiol Pharm Pharmacol. (2016), [cited March 14, 2024]; 6(1): 52-58. doi:10.5455/njppp.2015.5.2909201580



Harvard Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami (2016) Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats. Natl J Physiol Pharm Pharmacol, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580



Turabian Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. 2016. Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats. National Journal of Physiology, Pharmacy and Pharmacology, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580



Chicago Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. "Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 52-58. doi:10.5455/njppp.2015.5.2909201580



MLA (The Modern Language Association) Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami. "Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats." National Journal of Physiology, Pharmacy and Pharmacology 6.1 (2016), 52-58. Print. doi:10.5455/njppp.2015.5.2909201580



APA (American Psychological Association) Style

Teuku Heriansyah, Titin Andri Wihastuti, Kenty Wantri Anita, Agustin Iskandar, Riski Bagus Suhendra, Patan Ahmad Setiabudi, Lintang Widya Sishartami (2016) Atherogenesis inhibition by darapladib administration in dyslipidemia model Sprague–Dawley rats. National Journal of Physiology, Pharmacy and Pharmacology, 6 (1), 52-58. doi:10.5455/njppp.2015.5.2909201580